Adjunctive Use of Halobetasol Propionate-Tazarotene in Biologic-Experienced Patients With Psoriasis.
Sign Up to like & getrecommendations! Published in 2022 at "Cutis"
DOI: 10.12788/cutis.0451
Abstract: Not all patients with psoriasis achieve a satisfactory response to their initial biologic monotherapy. Switching to a new biologic may be associated with new safety issues and additional costs. In this study, we assessed the… read more here.
Keywords: patients psoriasis; biologic; propionate tazarotene; halobetasol propionate ... See more keywords